Trials / Recruiting
RecruitingNCT06920043
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Boston Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efimosfermin | Efimosfermin will be administered as a subcutaneous injection. |
| DRUG | Placebo | Placebo will be administered as a subcutaneous injection. |
Timeline
- Start date
- 2025-04-09
- Primary completion
- 2027-11-01
- Completion
- 2027-12-01
- First posted
- 2025-04-09
- Last updated
- 2025-12-24
Locations
35 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06920043. Inclusion in this directory is not an endorsement.